Study Details

Back to Search Results

Study of FK463 for the Treatment of Invasive Aspergillosis

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT00036166

Astellas Study ID

The unique identification code given by the study sponsor.

FG463-21-01

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Infections

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 Years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jan 1999 - Jan 2002

Masking

None (Open Label)

Enrollment number

326

An Open-Label, Non-Comparative Study of FK463 for the Treatment of Invasive Aspergillosis

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Study of FK463 for the Treatment of Invasive Aspergillosis? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Universitat Wurzburg, Institut fur Molekulare und Infectionsbiologie

Wurzburg, Germany, E-97070

LMU Munchen, Hamatopoetische Zell - Transplantation

Munchen, Germany, D-81366

Westpfalz Krankehaus

Kaiserslautern, Germany, D-67655

Medizinische Klinik und Poliklinik II, Abt. Hamatologie und Onkologie

Leipzig, Germany, D-04103

Uniklinik Mainz

Mainz, Germany, 55101

Royal Free Hospital, Dept. of Haematological Oncology

London, United Kingdom, NW3 2QG

Hopital Saint Louis, Service D'Hematologie/Greffe de Moelle

Paris, France, 10

Hopital Henri Mondor, Service d'Hematologie Clinique

Creteil, France, 94010

Ospedale Niguarda-Ca Granda, Dept. of Internal Medicine Padiglione Brera

Milano, Italy, 20162

Hospital Clinic I provencial, Servicio Enfermadades Infecciosas

Barcelona, Spain, ES 28041

Hospital Doce de Octubre, Servicio de Microbiologia y Enfermadades Infecciosas

Madrid, Spain, ES 28041

Hospital Gregorio Maranon, Servicio de Enfermadades Infecciosas

Madrid, Spain, ES 28007

Medizinische Univ.-Klinik

Graz, Austria, 8036

Huddinge University Hospital, Dept. of Transplantation Surgery/Immunology

Huddinge, Sweden, SE141 86

Nationale Institute for Cancer Research

Genova, Italy, I 16132

Krankenhaus Elisabethinen Linz

Linz, Austria, A-4010

Christie Hospital NHS Trust

Manchester, United Kingdom, M20 4BX

Klinikum der Stadt, Medizinische Klinik A

Ludwigshafen, Germany, D-67063

Johann Wolfgang Goethe Universitat, Medizinische Klinik III

Frankfurt, Germany, D-60590

Royal Marsden Hospital

Sutton Surrey, United Kingdom, SM2 5PT

Institute of Haematology and Blood Transfusion

Warsaw, Poland, 00-957

Hopital Necker Enfants Malades, Service d'Hematologie

Paris, France, 75015

Hotel Dieu, Service d'Hematologie

Nantes, France, 44093

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo